SUNNYVALE, Calif.--(BUSINESS WIRE)-- , a global leader in materials testing services, is expanding its battery materials testing capabilities with a new purpose-built 6,600 square-foot laboratory located in Sunnyvale, CA. and expanded facilities at its Syracuse, New York laboratory with the addition of 6,500 square-foot of new laboratory space. Both laboratories further complement Eurofins EAG Laboratories’ extensive testing techniques and capabilities covering over 150 material testing techniques. Eurofins EAG is the only independent battery testing laboratory with ‘turnkey’ materials and f...
Atos: weak Q1 2024 results, need for fresh funds has already increasedVerisure launches a new term loan; new bonds to followVerallia: Q1 2024 logically weak but the recovery in demand is confirmedAngloAmerican Plc: Takeover offer from BHP Group for the entire share capital>...
Atos : faibles résultats au T1 2024, les besoins de nouveaux fonds a augmentéVerisure lance un nouveau term loan ; des nouvelles obligations suivrontVerallia : T1 2024 logiquement faible mais la reprise de la demande se confirmeAngloAmerican PLC : Offre de rachat sur la totalité du capital par BHP>...
Having flirted with the 495-point mark on Friday, which could have triggered an extension of the correction, the market has rebounded well since then. Our technical analysis highlights a configuration in which we are only at the start of a powerful rally. Target of 622 points for Stoxx 600 index (+11%) by the end of the year confirmed. Prefer banks to insurance companies in the short term. - ...
Après avoir frôlé vendredi la barre des 495 points qui aurait pu déclencher la poursuite de la correction, le marché a ensuite bien rebondi. Notre analyse technique met en lumière une configuration où nous ne serions qu’au début d’un rallye puissant. Objectif 622 points (+11%) d’ici à la fin de l’année confirmé sur le Stoxx 600. Préférer les banques aux assurances à court terme. - ...
>An excessive sell-off? - The group held its conference call yesterday at 3pm and the stock closed down 8%:The share price had risen by 31% over the past six months, creating the conditions for profit-taking and potentially short positions by investors most critical of the group’s communication.As happened after full-year results were released, yesterday’s sell-off appears severe to us in view of: i/ the results reported in Q1; and ii/ potential impacts in ...
>Une sanction trop sévère ? - Le groupe a tenu sa conf call hier à 15h, et le titre a clôturé à -8% : Le cours avait progressé de 31% sur les 6 derniers mois, créant de facto les conditions de prise de profits, ou éventuellement de short pour les investisseurs les plus critiques de la communication du groupe.Comme lors des résultats annuels, la sanction boursière d’hier nous apparait sévère au regard 1/ de ce qui a été publié au titre du T1 et 2/ de ce qui ...
>CA T1 : 6.8% sur l’organique Core business, 5.5% non ajusté d’un jour travaillé - Eurofins publie un CA T1 de 1 653 M€, en hausse de 5.0% légèrement en dessous de nos estimations (1 717 M€) et de celles du consensus Visible Alpha (1 699 M€). Ajusté d’un jour de travail en moins de c. 1.3%, la croissance organique Core Business est ressortie à 6.8% i.e un niveau légèrement supérieur à la guidance du groupe de 6.5%. en publié, le LFL Core Business ressort à 5.5% (sur...
>Q1 revenues: 6.8% organic growth in core business, 5.5% not adjusted for a working day - Eurofins reported Q1 revenues of € 1,653m, up 5.0%, slightly below our estimates (€ 1,717m) and Visible Alpha consensus (€ 1,699m). Adjusted by one less working day of around 1.3%, core business organic growth came in at 6.8%, i.e. slightly above the group's guidance of 6.5%. In published figures, core Business LFL growth came in at 5.5% (for Visible Alpha, the figure given was ...
Moody's Ratings has completed a periodic review of the ratings of Eurofins Scientific SE and other ratings that are associated with this issuer. The review was conducted through a rating committee held on 22 March 2024 in which Moody's reassessed the appropriateness of the ratings in the context of...
LUXEMBOURG--(BUSINESS WIRE)-- Regulatory News: Eurofins (Paris:ERF): EUROFINS SCIENTIFIC SE Société Européenne Siège social : 23, Val Fleuri, L-1526 Luxembourg Registre de Commerce et des Sociétés Luxembourg B167775 (la « Société ») Les actionnaires de la Société, et uniquement avec voix consultative les porteurs de Deeply Subordinated Fixed to Floating Rate Bonds (ISIN: XS1716945586 et XS2579480307) et/ou de Senior Unsecured Euro Bonds (ISIN: XS1651444140, XS2167595672, XS2491664137, XS2676883114, et XS2343114687) émis par la Société, sont invités à participer à l’assemblée générale ord...
SAN DIEGO--(BUSINESS WIRE)-- , an industry-leading provider of products and services for drug discovery research, today announced the launch of DiscoveryAI SAFIRE (Suite of ADMET Predictions For In Silico Refinement and Evaluation). SAFIRE is an advanced platform that leverages proprietary datasets, artificial intelligence (AI), and machine learning (ML), offering a unique capability for expediting discovery. SAFIRE is now available for customer use through the website. Eurofins Discovery’s experienced informatics experts collected vast, high-quality and diverse datasets that provide a uniq...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.